Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Convertible loan update

26 Jan 2006 16:38

For Immediate Release 26 January 2006 LiDCO GROUP PLC (LiDCO or "The Company") Laurus Convertible Loan Facility In line with the AIM Rules, the Board of LiDCO (AIM: LID), the cardiovascularmonitoring company, today announces that it has drawndown a further instalmentof the US$2 million three year secured revolving convertible loan raised on10th August 2005 from Laurus Master Fund, Ltd. ("Laurus"), which is now fullyutilised.For further information please contact: LiDCO Group Plc Terry O'Brien, Chief Executive 020 7749 1500 Hugh McGarel-Groves, Finance Director Buchanan Communications Tim Anderson, Mary-Jane Johnson, James Strong 020 7466 5000 Panmure Gordon Aubrey Powell, Katherine Roe 020 7459 3600 Notes to EditorsAbout Laurus Capital Management LLCLaurus is a US based financial institution that provides finance to small andmicro cap growth companies. Their flexible financing solutions are designed tohelp build cash reserves and enable management to focus on operations andstrategic growth opportunities.About LiDCO Group PlcLiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier ofminimally invasive, computer-based hemodynamic monitoring equipment anddisposables used primarily for the management of critical care andcardiovascular risk hospital patients. Use of LiDCO's technology has been shownto significantly reduce the complications (particularly infections) and costsassociated with major surgery. The technology was invented in the Department ofApplied Physiology based at St Thomas' Hospital, London where the Companymaintains a research base.ENDLIDCO GROUP PLC

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.